Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer / Conteduca, V; Crabb, Sj; Jones, Rj; Caffo, O; Elliott, T; Scarpi, E; Fabbri, P; Derosa, L; Massari, F; Numico, G; Zarif, S; Hanna, C; Maines, F; Joyce, H; Lolli, C; De Giorgi, U.. - In: PLOS ONE. - ISSN 1932-6203. - 2016:11(7)(2016), p. e0158952. [10.1371/journal.pone.0158952]
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
Caffo O;
2016-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
